Skip to content

Greek Registry - Familial Hypercholesterolaemia

Hellenic Registry for Familial Hypercholesterolemia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03140605
Acronym
GRegistry-FH
Enrollment
1000
Registered
2017-05-04
Start date
2017-01-10
Completion date
2022-12-10
Last updated
2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Hypercholesterolemia

Brief summary

Familial hypercholesterolemia (FH) \[heterozygous (heFH) or homozygous FH (hoFH)\] is a common genetic disorder, characterized by elevated plasma low density lipoprotein (LDL) cholesterol concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and extensor tendons, rapidly progressing vascular disease, and aortic valve disease.

Detailed description

In contrast, timely recognition and effective treatment of FH can result in a significant improvement in clinical outcomes. The problem is that that majority of individuals with FH are unaware of their disease, particularly that the disease remains silent for many years. In most countries around the world \<5% of individuals with FH are identified . Until lately the prevalence of heFH was traditionally considered to be \ 1:500 individuals , although clinical and genetic studies suggest that heFH affects \ 1:200-250 individuals . Thus, the aim of the Hellenic College of Treatment of Atherosclerosis (HCAT) is to 1). Evaluate the prevalence of FH in Greece (FHG-Registry) and 2). To inform population of FH disease.

Interventions

None listed

Sponsors

Hellenic College of Treatment of Atherosclerosis
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* both genders * \>18 years, \<80 years * door to door enrolment * eligible to sign informed consent

Exclusion criteria

* \<18 years, \>80 years * deny to sign informed consent

Design outcomes

Primary

MeasureTime frameDescription
the prevalence of Familiar Hypercholesterolaemia in Greece1 monthpatients with FH will be screened and include in Registry

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026